13
Participants
Start Date
July 27, 2020
Primary Completion Date
December 31, 2023
Study Completion Date
December 1, 2024
INCB7839
INCB7839 dosing will begin at 120 mg/m2/dose BID which is equivalent to the adult RP2D (200 mg PO BID) based on a typical adult size of 1.67m2. The INCB7839 dose may be decreased to 80 mg/m2/dose BID if the staring dose is not tolerable. 28 consecutive days (4 weeks) will constitute one course. Patients may continue to receive INCB7839 for 26 courses (approximately 2 years).
Memorial Sloan Kettering Cancer Center, New York
Children Hospital of Pittsburgh, Pittsburgh
Children's National Medical Center, Washington D.C.
St. Jude Children's Research Hospital, Memphis
Cincinnati Children Hospital Medical Center, Cincinnati
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Texas Children's Hospital, Houston
Children's Hospital Colorado, Aurora
Children's Hospital Los Angeles, Los Angeles
Stanford University and Lucile Packard Children's Hospital, Palo Alto
Dana Farber Cancer Institute, Boston
National Cancer Institute (NCI)
NIH
American Lebanese Syrian Associated Charities
OTHER
Pediatric Brain Tumor Consortium
NETWORK